-
Binimetinib, sold
under the
brand name M****vi, is an anti-cancer
medication used to
treat various cancers.
Binimetinib is a
selective inhibitor of MEK...
- BioPharma. In June 2018, it was
approved by the FDA in
combination with
binimetinib for the
treatment of
people with
unresectable or
metastatic BRAF V600E...
-
especially BRAF-mutated melanoma, and KRAS/BRAF
mutated colorectal cancer.
Binimetinib (MEK162),
approved by the FDA in June 2018 in
combination with encorafenib...
- the
combination of a BRAF
inhibitor encorafenib and a MEK
inhibitor binimetinib for the
treatment of un-resectable or
metastatic melanoma with a BRAF...
- both as a
monotherapy and in
combination with
other agents, such as
binimetinib and crizotinib. Cao L, Chen S, Sun R,
Ashby CR, Wei L,
Huang Z, et al...
-
acquisition of two
Phase III cancer-drug candidates; the MEK
inhibitor binimetinib (MEK 162) and the BRAF
inhibitor encorafenib (LGX818), for $85 million...
-
Pfizer acquired the
company for
approximately $11 billion. M****VI (
Binimetinib) -
selective MEK
inhibitor -
Approved 2018,
acquired by
Pfizer TUKYSA...
- vemurafenib. Some MEK
inhibitors include cobimetinib, CI-1040, PD0325901,
binimetinib (MEK162), selumetinib, and
trametinib (GSK1120212) It has been found...
- C, et al. (2014). "A
phase 1b/2
study of LEE011 in
combination with
binimetinib (MEK162) in
patients with NRAS-mutant melanoma:
Early encouraging clinical...
-
Filgotinib Lestaurtinib Momelotinib Pacritinib Ruxolitinib MAP2K (MEK)
Binimetinib Cobimetinib Mirdametinib Selumetinib Trametinib EML4-ALK
Crizotinib Entrectinib...
